An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.

Published in: Expert opinion on drug safety (2021)

FRCs represent an efficacious option for treatment intensification from basal insulin or even the first insulin-based therapy in T2DM. Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists.

Keyphrases

type diabetes
glycemic control
body weight
blood glucose
stem cells
insulin resistance
blood pressure
metabolic syndrome
weight loss
adipose tissue
bone marrow